Trial Profile
A Phase I Trial of Osimertinib (AZD9291) and Necitumumab in EGFR-Mutant Non-Small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Necitumumab (Primary) ; Osimertinib (Primary)
- Indications Carcinoma; Non-small cell lung cancer
- Focus Adverse reactions
- 01 Jul 2023 Planned End Date changed from 30 Jun 2023 to 30 Jun 2024.
- 01 Jul 2023 Planned primary completion date changed from 30 Jun 2023 to 30 Jun 2024.
- 01 Jul 2022 Planned End Date changed from 30 Jun 2022 to 30 Jun 2023.